Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder

A 12-week prospective open-label multicentre study

Chi Un Pae, Hong Jin Jeon, Boung Chul Lee, Ho Jun Seo, Shin Gyeom Kim, E. Jin Park, Won Kim, Kyung Phil Kwak, Changsu Han, Seong Jin Cho, Sang Woo Hahn, Duk In Jon, Jin Hyuk Choi, Tae Youn Jun

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Patients with chronic or recurrent major depressive disorder (MDD) have faced a dearth of treatment options. The present study evaluated the effectiveness and tolerability of aripiprazole augmentation for the treatment of chronic or recurrent MDD. This was the first 12-week prospective, multicentre, open-label study of the effectiveness and tolerability of flexibly dosed aripiprazole as an augmentation to ongoing antidepressant treatment in patients with chronic or recurrent MDD. The primary outcome measure for effectiveness was changes between baseline and endpoint (week 12) in total scores on the Montgomery-Asberg Depression Rating Scale. Adverse events (AEs) occurring throughout the trial are also reported. The Montgomery-Asberg Depression Rating Scale total scores decreased significantly between the baseline and the endpoint (magnitude of difference=-11.6, P<0.0001). At the endpoint, the response rate was 55.2% and the remission rate was 41.3%. Adjunctive aripiprazole treatment administered from week 1 through the endpoint was associated with remission and significant treatment responses. More than half (55.8%) of those taking adjunctive aripiprazole completed the study and relatively few patients discontinued participation because of AEs. None of the patients discontinued participation in the study because of an inadequate therapeutic response. Common AEs included headache, akathisia, insomnia and constipation. The mean dose of aripiprazole at the endpoint was 6.6 mg/day. Adjunctive aripiprazole may be effective and tolerable for patients with chronic or recurrent MDD. Adequately powered and controlled clinical trials should be conducted to confirm our open-label study findings.

Original languageEnglish
Pages (from-to)322-329
Number of pages8
JournalInternational Clinical Psychopharmacology
Volume28
Issue number6
DOIs
Publication statusPublished - 2013 Nov 1

Fingerprint

compound A 12
Major Depressive Disorder
Multicenter Studies
Patient Participation
Therapeutics
Depression
Psychomotor Agitation
Controlled Clinical Trials
Sleep Initiation and Maintenance Disorders
Constipation
Antidepressive Agents
Headache
Aripiprazole
Outcome Assessment (Health Care)

Keywords

  • Antidepressant
  • Aripiprazole
  • Augmentation
  • Chronic depression
  • Recurrent depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder : A 12-week prospective open-label multicentre study. / Pae, Chi Un; Jeon, Hong Jin; Lee, Boung Chul; Seo, Ho Jun; Kim, Shin Gyeom; Park, E. Jin; Kim, Won; Kwak, Kyung Phil; Han, Changsu; Cho, Seong Jin; Hahn, Sang Woo; Jon, Duk In; Choi, Jin Hyuk; Jun, Tae Youn.

In: International Clinical Psychopharmacology, Vol. 28, No. 6, 01.11.2013, p. 322-329.

Research output: Contribution to journalReview article

Pae, Chi Un ; Jeon, Hong Jin ; Lee, Boung Chul ; Seo, Ho Jun ; Kim, Shin Gyeom ; Park, E. Jin ; Kim, Won ; Kwak, Kyung Phil ; Han, Changsu ; Cho, Seong Jin ; Hahn, Sang Woo ; Jon, Duk In ; Choi, Jin Hyuk ; Jun, Tae Youn. / Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder : A 12-week prospective open-label multicentre study. In: International Clinical Psychopharmacology. 2013 ; Vol. 28, No. 6. pp. 322-329.
@article{16f0ed7be7244a4f832e482ff22dcac0,
title = "Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder: A 12-week prospective open-label multicentre study",
abstract = "Patients with chronic or recurrent major depressive disorder (MDD) have faced a dearth of treatment options. The present study evaluated the effectiveness and tolerability of aripiprazole augmentation for the treatment of chronic or recurrent MDD. This was the first 12-week prospective, multicentre, open-label study of the effectiveness and tolerability of flexibly dosed aripiprazole as an augmentation to ongoing antidepressant treatment in patients with chronic or recurrent MDD. The primary outcome measure for effectiveness was changes between baseline and endpoint (week 12) in total scores on the Montgomery-Asberg Depression Rating Scale. Adverse events (AEs) occurring throughout the trial are also reported. The Montgomery-Asberg Depression Rating Scale total scores decreased significantly between the baseline and the endpoint (magnitude of difference=-11.6, P<0.0001). At the endpoint, the response rate was 55.2{\%} and the remission rate was 41.3{\%}. Adjunctive aripiprazole treatment administered from week 1 through the endpoint was associated with remission and significant treatment responses. More than half (55.8{\%}) of those taking adjunctive aripiprazole completed the study and relatively few patients discontinued participation because of AEs. None of the patients discontinued participation in the study because of an inadequate therapeutic response. Common AEs included headache, akathisia, insomnia and constipation. The mean dose of aripiprazole at the endpoint was 6.6 mg/day. Adjunctive aripiprazole may be effective and tolerable for patients with chronic or recurrent MDD. Adequately powered and controlled clinical trials should be conducted to confirm our open-label study findings.",
keywords = "Antidepressant, Aripiprazole, Augmentation, Chronic depression, Recurrent depression",
author = "Pae, {Chi Un} and Jeon, {Hong Jin} and Lee, {Boung Chul} and Seo, {Ho Jun} and Kim, {Shin Gyeom} and Park, {E. Jin} and Won Kim and Kwak, {Kyung Phil} and Changsu Han and Cho, {Seong Jin} and Hahn, {Sang Woo} and Jon, {Duk In} and Choi, {Jin Hyuk} and Jun, {Tae Youn}",
year = "2013",
month = "11",
day = "1",
doi = "10.1097/YIC.0b013e3283643728",
language = "English",
volume = "28",
pages = "322--329",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Aripiprazole augmentation for treatment of patients with chronic or recurrent major depressive disorder

T2 - A 12-week prospective open-label multicentre study

AU - Pae, Chi Un

AU - Jeon, Hong Jin

AU - Lee, Boung Chul

AU - Seo, Ho Jun

AU - Kim, Shin Gyeom

AU - Park, E. Jin

AU - Kim, Won

AU - Kwak, Kyung Phil

AU - Han, Changsu

AU - Cho, Seong Jin

AU - Hahn, Sang Woo

AU - Jon, Duk In

AU - Choi, Jin Hyuk

AU - Jun, Tae Youn

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Patients with chronic or recurrent major depressive disorder (MDD) have faced a dearth of treatment options. The present study evaluated the effectiveness and tolerability of aripiprazole augmentation for the treatment of chronic or recurrent MDD. This was the first 12-week prospective, multicentre, open-label study of the effectiveness and tolerability of flexibly dosed aripiprazole as an augmentation to ongoing antidepressant treatment in patients with chronic or recurrent MDD. The primary outcome measure for effectiveness was changes between baseline and endpoint (week 12) in total scores on the Montgomery-Asberg Depression Rating Scale. Adverse events (AEs) occurring throughout the trial are also reported. The Montgomery-Asberg Depression Rating Scale total scores decreased significantly between the baseline and the endpoint (magnitude of difference=-11.6, P<0.0001). At the endpoint, the response rate was 55.2% and the remission rate was 41.3%. Adjunctive aripiprazole treatment administered from week 1 through the endpoint was associated with remission and significant treatment responses. More than half (55.8%) of those taking adjunctive aripiprazole completed the study and relatively few patients discontinued participation because of AEs. None of the patients discontinued participation in the study because of an inadequate therapeutic response. Common AEs included headache, akathisia, insomnia and constipation. The mean dose of aripiprazole at the endpoint was 6.6 mg/day. Adjunctive aripiprazole may be effective and tolerable for patients with chronic or recurrent MDD. Adequately powered and controlled clinical trials should be conducted to confirm our open-label study findings.

AB - Patients with chronic or recurrent major depressive disorder (MDD) have faced a dearth of treatment options. The present study evaluated the effectiveness and tolerability of aripiprazole augmentation for the treatment of chronic or recurrent MDD. This was the first 12-week prospective, multicentre, open-label study of the effectiveness and tolerability of flexibly dosed aripiprazole as an augmentation to ongoing antidepressant treatment in patients with chronic or recurrent MDD. The primary outcome measure for effectiveness was changes between baseline and endpoint (week 12) in total scores on the Montgomery-Asberg Depression Rating Scale. Adverse events (AEs) occurring throughout the trial are also reported. The Montgomery-Asberg Depression Rating Scale total scores decreased significantly between the baseline and the endpoint (magnitude of difference=-11.6, P<0.0001). At the endpoint, the response rate was 55.2% and the remission rate was 41.3%. Adjunctive aripiprazole treatment administered from week 1 through the endpoint was associated with remission and significant treatment responses. More than half (55.8%) of those taking adjunctive aripiprazole completed the study and relatively few patients discontinued participation because of AEs. None of the patients discontinued participation in the study because of an inadequate therapeutic response. Common AEs included headache, akathisia, insomnia and constipation. The mean dose of aripiprazole at the endpoint was 6.6 mg/day. Adjunctive aripiprazole may be effective and tolerable for patients with chronic or recurrent MDD. Adequately powered and controlled clinical trials should be conducted to confirm our open-label study findings.

KW - Antidepressant

KW - Aripiprazole

KW - Augmentation

KW - Chronic depression

KW - Recurrent depression

UR - http://www.scopus.com/inward/record.url?scp=84885301928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885301928&partnerID=8YFLogxK

U2 - 10.1097/YIC.0b013e3283643728

DO - 10.1097/YIC.0b013e3283643728

M3 - Review article

VL - 28

SP - 322

EP - 329

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 6

ER -